GERD 2003 - A consensus on the way ahead

被引:36
作者
Moss, SF
Armstrong, D
Arnold, R
Ferenci, P
Fock, KM
Holtmann, G
McCarthy, DM
Moraes-Filho, JP
Mutschler, E
Playford, R
Spechler, SJ
Stanghellini, V
Modlin, IM
机构
[1] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA
[2] Brown Univ, Providence, RI 02912 USA
[3] Univ New Mexico, Sch Med, Albuquerque, NM 87131 USA
[4] Univ Texas, SW Med Ctr, Dallas, TX 75235 USA
[5] McMaster Univ, Hamilton, ON L8S 4L8, Canada
[6] Univ Marburg, D-35032 Marburg, Germany
[7] Univ Essen Gesamthsch, Essen, Germany
[8] Univ Vienna, Clin Internal Med, A-1095 Vienna, Austria
[9] Changi Gen Hosp, Singapore, Singapore
[10] Univ Sao Paulo, Sch Med, BR-05508 Sao Paulo, Brazil
[11] Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England
[12] Univ Bologna, I-40126 Bologna, Italy
关键词
gastroesophageal reflux disease; esophagitis; management;
D O I
10.1159/000071290
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Gastroesophageal reflux disease (GERD) has in recent times become an important public health issue owing to the considerable health care resources utilized in its management, its deleterious effect on quality of life and the increasing prevalence of a relatively rare complication of reflux disease - esophageal adenocarcinoma. We review here the major current challenges in the field of reflux disease and its complications, and provide some approaches that may be useful in management. The issues to be faced include the very limited comprehension of the reasons behind the increasing prevalence of the disease, difficulties in correlating symptoms with objective data of pathological gastroesophageal reflux and the relatively unsophisticated tools we are employing to investigate the underlying pathophysiology. It is certain that the lack of well-defined and characterized methodologies to compare the effects of therapy require the development of more effective questionnaire-type analytic tools. In regard to treatment, there is little doubt that the widely prescribed proton pump inhibitors have dose-equivalent efficacy and are the most highly effective agents capable of suppressing acid, controlling many of the symptoms of GERD and healing erosions. Nevertheless, many patients continue to experience symptoms on withdrawal or at night. Pharmacological agents that can effectively increase lower esophageal sphincter pressure or promote motility are as yet unavailable. Although the introduction of laparoscopic techniques has resulted in a modest revival in surgical intervention using a variety of 'wrap-type' operations, the indications are few and the procedure is associated with a significant morbidity and even mortality especially if the expertise of the surgeon is an issue. Endoscopic techniques of regulating reflux are at this time experimental and not applicable to the general population. Intestinal metaplasia in the lower esophagus is probably very common. Whether and how to, first, screen for, and then, perform surveillance in Barrett's esophagus remains highly problematic and contentious. Copyright (C) 2003 S. Karger AG, Basel.
引用
收藏
页码:111 / 117
页数:7
相关论文
共 35 条
[1]  
Bozymski EM, 1997, AM J GASTROENTEROL, V92, P556
[2]  
*BRIT SOC GASTR, 2003, DYSP MAN GUID
[3]   Endoscopy-negative reflux disease [J].
Carlsson, R ;
Holloway, RH .
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2000, 14 (05) :827-837
[4]   Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole [J].
Carlsson, R ;
Dent, J ;
Watts, R ;
Riley, S ;
Sheikh, R ;
Hatlebakk, J ;
Haug, K ;
de Groot, G ;
van Oudvorst, A ;
Dalvag, A ;
Junghard, O ;
Wiklund, I .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1998, 10 (02) :119-124
[5]  
Castell DO, 2002, AM J GASTROENTEROL, V97, P575
[6]  
Castell DO, 2001, AM J MANAG CARE, V7, pS15
[7]   Measuring symptom distress and health-related quality of life in clinical trials of gastroesophageal reflux disease treatment: Further validation of the Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS) [J].
Damiano, A ;
Handley, K ;
Adler, E ;
Siddique, R ;
Bhattacharyja, A .
DIGESTIVE DISEASES AND SCIENCES, 2002, 47 (07) :1530-1537
[8]   Clinical significance of the cytochrome P4502C19 genetic polymorphism [J].
Desta, Z ;
Zhao, XJ ;
Shin, JG ;
Flockhart, DA .
CLINICAL PHARMACOKINETICS, 2002, 41 (12) :913-958
[9]  
Eissele R, 2002, GASTROENTEROLOGY, V122, pA582
[10]   Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough [J].
Fackler, WK ;
Ours, TM ;
Vaezi, MF ;
Richter, JE .
GASTROENTEROLOGY, 2002, 122 (03) :625-632